Deutsche Bank AG acquired a new position in CytomX Therapeutics, Inc. (NASDAQ:CTMX – Free Report) in the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund acquired 663,038 shares of the biotechnology company’s stock, valued at approximately $2,486,000.
A number of other institutional investors also recently made changes to their positions in CTMX. Wells Fargo & Company MN lifted its stake in CytomX Therapeutics by 83.2% in the fourth quarter. Wells Fargo & Company MN now owns 6,605 shares of the biotechnology company’s stock worth $28,000 after purchasing an additional 3,000 shares during the last quarter. Invesco Ltd. bought a new position in shares of CytomX Therapeutics during the second quarter valued at about $32,000. Goldman Sachs Group Inc. bought a new position in shares of CytomX Therapeutics during the first quarter valued at about $39,000. May Hill Capital LLC purchased a new position in shares of CytomX Therapeutics in the fourth quarter worth about $46,000. Finally, Lido Advisors LLC purchased a new position in shares of CytomX Therapeutics in the first quarter worth about $49,000. Hedge funds and other institutional investors own 67.77% of the company’s stock.
CytomX Therapeutics Trading Up 3.0%
Shares of CytomX Therapeutics stock opened at $3.42 on Friday. The firm has a market capitalization of $745.22 million, a P/E ratio of -6.84 and a beta of 2.12. CytomX Therapeutics, Inc. has a 12 month low of $1.90 and a 12 month high of $8.21. The business has a fifty day simple moving average of $3.45 and a two-hundred day simple moving average of $4.04.
Wall Street Analysts Forecast Growth
Several brokerages recently weighed in on CTMX. JPMorgan Chase & Co. dropped their target price on CytomX Therapeutics from $12.00 to $11.00 and set an “overweight” rating for the company in a report on Thursday, August 13th. Guggenheim decreased their price target on CytomX Therapeutics from $15.00 to $14.00 and set a “buy” rating on the stock in a research note on Monday, August 10th. Zacks Research downgraded CytomX Therapeutics from a “strong-buy” rating to a “hold” rating in a research report on Wednesday, August 19th. Wall Street Zen lowered CytomX Therapeutics from a “hold” rating to a “sell” rating in a research note on Sunday, August 23rd. Finally, Wolfe Research began coverage on shares of CytomX Therapeutics in a report on Tuesday, May 19th. They issued an “outperform” rating and a $6.00 target price on the stock. One equities research analyst has rated the stock with a Strong Buy rating, nine have given a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average target price of $11.90.
Check Out Our Latest Report on CytomX Therapeutics
CytomX Therapeutics Profile
CytomX Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of next-generation therapeutics based on its proprietary Probody® platform. The company engineers masked antibody prodrugs that remain inactive in healthy tissue but are selectively activated in the tumor microenvironment. This approach is designed to enhance the safety and tolerability of antibody-based therapies, particularly those targeting immuno-oncology pathways.
At the core of CytomX’s pipeline is Pacmilimab (CX-072), an anti–PD-L1 Probody therapeutic currently undergoing clinical evaluation for multiple solid tumor indications.
Read More
- Five stocks we like better than CytomX Therapeutics
- Nutanix’s Rally Has a Bigger Story Than Earnings as AMD’s AI Bet Takes Shape
- SEC Probe Puts Wall Street Leverage Risk Back in Focus
- A Bearish-Dollar Options Surge Raises the Stakes for Warsh at Jackson Hole
- Five Below’s Turnaround Is Working—But Has the Stock Run Too Far?
Want to see what other hedge funds are holding CTMX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for CytomX Therapeutics, Inc. (NASDAQ:CTMX – Free Report).
Receive News & Ratings for CytomX Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CytomX Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
